Visceral pain is pain that results from the activation of nociceptors of the thoracic, pelvic, or abdominal viscera (organs). Visceral structures are highly sensitive to distension (stretch), ischemia and inflammation, but relatively insensitive to other stimuli that normally evoke pain such as cutting or burning. Visceral pain is diffuse, difficult to localize and often referred to a distant, usually superficial, structure. It may be accompanied by symptoms such as nausea, vomiting, changes in vital signs as well as emotional manifestations. The pain may be described as sickening, deep, squeezing, and dull. Distinct structural lesions or biochemical abnormalities explain this type of pain in only a proportion of patients. These diseases are grouped under gastrointestinal neuromuscular diseases (GINMD). Others can experience visceral pains, often very intense in nature, without any evidence of structural, biochemical or histolopathologic reason for such symptoms. These diseases are grouped under functional gastrointestinal disorders (FGID) and the pathophysiology and treatment can vary greatly from GINMD. The two major single entities among functional disorders of the gut are functional dyspepsia and irritable bowel syndrome.
Growing focus on research and development by pharmaceutical companies and government initiatives are expected to boost the visceral pain industry over the forecast period. The market is projected to witness significant gain during the forecast period owing to increasing collaboration within pharmaceutical companies. Moreover, growth in the interest of scientists and researchers in studying the pain originating from internal organs has mirrored in the consciousness of the importance of visceral pain in patients. Asia Pacific is expected to grow at the highest CAGR of 6.2% from 2017 to 2024. North America has been leading the market for visceral pain, it is expected that African countries will witness exponential growth during the forecast period.

Market Analysis and Insights: Global Visceral Pain Market
The global Visceral Pain market size is projected to reach US$ 1315.3 million by 2027, from US$ 989.4 million in 2020, at a CAGR of 3.7% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Visceral Pain market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Visceral Pain market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Visceral Pain market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Visceral Pain market.

Global Visceral Pain Scope and Market Size
Visceral Pain market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Visceral Pain market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Analgesics
Pain Modifiers

Segment by Application
Interstitial Cystitis
Crohn’s
Irritable Bowel
Chronic Prostatitis

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Pfizer
Johnson & Johnson
Abbvie
Takeda
Allergan
AstraZeneca